Diagnostic Fundraising

Overall Landscape:

Under Pressure but Showing Signs of Recovery

The diagnostics/tools (Dx/Tools) sector has faced more headwinds than other healthcare subsectors in recent years. The Dx/Tools sector continues to face pressure even as healthtech and devices have stayed more stable. That said, there are positive signals: investments in Dx/Tools are slowly rising , and certain niches are performing quite well.

Bright Spots in Diagnostics

Liquid biopsies and precision diagnostics companies are showing strength, combining their close relationship to the success of precision therapy with a relatively untapped potential to collect and aggregate data. A standout example: Freenome has raised $1.5 billion for its cancer detection blood tests.

AI as the Central Driver

AI is transforming diagnostics fundraising. Medical Diagnostics is one of the top-funded clusters in digital health, with AI cited as the common denominator. AI’s transformative capabilities in improving diagnostic accuracy continue to attract significant funding. More broadly, AI represents 46% of all healthcare investment in the venture-backed space.

Broader Healthcare VC Context

Venture capital investment in healthcare grew to $23 billion in 2024, from $20 billion in 2023. However, investors are writing fewer checks and taking longer to do so, driving a drop in both deal volume and dollars. The trend is toward larger bets on proven platforms: mega deals exceeding $100 million were particularly prominent in Q1 2025, dominating the funding landscape, signaling that investors favor mature platforms that have already demonstrated clinical impact, scalability, and monetization potential.

Philanthropic Fundraising

On the philanthropic side, contributions to the healthcare sector reached an all-time high in 2023, with the healthcare industry receiving $56.58 billion in philanthropic gifts and 4.4% inflation-adjusted growth. However, donor acquisition is softening: 51% of healthcare organizations indicate that their number of new donors has increased in the past 12 months, down from 65% the year before.

Key Takeaway

The diagnostics sector is navigating a selective funding environment where AI-enabled platforms — especially in cancer detection, precision diagnostics, and liquid biopsy — are attracting significant capital, while broader Dx/Tools investment remains constrained compared to biopharma AI and healthtech. Investors are being more discerning, favoring companies with proven clinical utility and clear paths to commercialization.​​​​​​​​​​​​​​​​